PRIVATE equity company TPG Capital Asia is considering a plan for an initial public offering of its pathology business in the region, said people with knowledge of the matter.
The buyout firm has asked banks to submit proposals for the potential listing of Pathology Asia Holdings, said the sources, who asked not to be named as the process is private. TPG is still weighing a listing venue for the business, and Singapore is among the options, they said.
TPG has expanded the business since it initially bought 39 pathology laboratories from Healthscope in 2018 for A$279 million (S$287.6 million), one source said. The operations are worth about US$2 billion (S$2.67 million) the person said.
Source: Business Times
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.